Clinical trialNCT02022540CompletedPhase 1Interventional

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

SponsorPanOptica, Inc.Enrollment50Age-Related Macular Degeneration (AMD)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Martin Wax, M.D.
PanOptica, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Colorado Springs, Colorado, United States
Facility name not stated
Winter Haven, Florida, United States
Facility name not stated
Shawnee Mission, Kansas, United States
Facility name not stated
Wichita, Kansas, United States
Facility name not stated
Boston, Massachusetts, United States
Facility name not stated
Portsmouth, New Hampshire, United States
Facility name not stated
Bloomfield, New Jersey, United States
Facility name not stated
Charlotte, North Carolina, United States
Facility name not stated
Durham, North Carolina, United States
Facility name not stated
Statesville, North Carolina, United States
Facility name not stated
Ashland, Oregon, United States
Facility name not stated
Philadelphia, Pennsylvania, United States
Facility name not stated
West Columbia, South Carolina, United States
Facility name not stated
Rapid City, South Dakota, United States
Facility name not stated
Nashville, Tennessee, United States
Facility name not stated
Abilene, Texas, United States
Facility name not stated
Austin, Texas, United States
Facility name not stated
Harlingen, Texas, United States
Facility name not stated
McAllen, Texas, United States
Facility name not stated
San Antonio, Texas, United States
Facility name not stated
Willow Park, Texas, United States
Facility name not stated
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ranibizumab →PAN-90806 Ophthalmic Solution

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2014
Primary completion: 31 Mar 2016
Completion: 31 May 2016
Last update posted: 28 Sept 2016
Registered enrollment: 50
Registry id: NCT02022540

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.